MedPath

Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia

Completed
Conditions
Euvolemic Hyponatremia
Hypervolemic Hyponatremia
Registration Number
NCT01240668
Lead Sponsor
Otsuka America Pharmaceutical
Brief Summary

The registry is a multi-center, prospective, observational study designed to collect data in patients with euvolemic and hypervolemic hyponatremia in the hospital setting in the USA and hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Europe; patients with hypovolemic hyponatremia will be excluded from the registry. The registry is observational in design, and the registry will collect data on patients with a serum sodium ≤130 mmol/L. Data from the patients' chart will be collected throughout the duration of the hospital, from admission to discharge, and the data will be entered into the case report form (CRF) or into an electronic data capture (EDC) system. These patients will be entered into the registry over the duration of 18 months at community, tertiary, and academic medical centers from diverse multiple regions of the USA and Europe.

A patient's treatment will be determined by their caregiver and not by this protocol. Thus, the registry will provide a unique opportunity to evaluate how the patients are managed under real-world management conditions.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
5028
Inclusion Criteria
  • Adults ≥18 years old who are hospitalized

  • Euvolemic or hypervolemic hyponatremia with serum sodium ≤130mmol/L

  • For euvolemic hyponatremia:

    • Euvolemia is defined as: absence of clinical and historical evidence of extracellular fluid volume depletion or sequestration; and absence of edema and ascites; or
    • Physician diagnosis of SIADH
  • For hypervolemic hyponatremia (applies to USA sites only):

    • Hypervolemia is defined as: excess extracellular fluid volume manifesting as dependent edema or ascites

    • Patients may have one or more of the following underlying co-morbid conditions:

      • Congestive heart failure
      • Cirrhosis and/or liver failure
      • Nephrotic syndrome
Exclusion Criteria
  • Patients with hypovolemic hyponatremia
  • Use of investigational drug, biologic, or device during the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time to initiation of hyponatremia treatmentHospital Discharge
Duration of hospital stay from time of first presentation of hyponatremia (which will be taken as the time of first presentation of hyponatremia for the current admission) to dischargeHospital Discharge
Change in serum sodium concentration from beginning of treatment period to the end of treatment period or discharge for a given hyponatremia treatmentHospital Discharge
Secondary Outcome Measures
NameTimeMethod
Medically necessary length of hospital stay and duration of intensive care unit (ICU) stayHospital Discharge
Relative proportions of etiologies associated with hyponatremiaHospital Discharge
Effectiveness of individual therapies in correcting hyponatremia and time taken to achieve the correction.Hospital Discharge

Effectiveness of individual therapies in correcting hyponatremia and time taken to achieve the correction measured as one of the following:

* serum sodium \>130

* serum sodium ≥135 mmol/L

* increase of serum sodium ≥5 mmol/L

Impact of hyponatremia on medically necessary length of stayHospital Discharge
Profile of investigations performed in diagnosing hyponatremiaHospital Discharge
Effectiveness of individual therapies in achieving symptom improvement measured as the number of reported symptoms at the start and end of treatment with a specific therapyHospital Discharge
Therapies used in the management of hyponatremiaHospital Discharge

Trial Locations

Locations (79)

North America Research Institute

🇺🇸

Azusa, California, United States

Chrishard Medical Group

🇺🇸

Inglewood, California, United States

UCLA

🇺🇸

Los Angeles, California, United States

Regional Cardiology Associates

🇺🇸

Sacramento, California, United States

Portercare Adventist Health System

🇺🇸

Denver, Colorado, United States

Georgetown University Hospital

🇺🇸

Washington, District of Columbia, United States

Memorial Healthcare System

🇺🇸

Hollywood, Florida, United States

Jacksonville Cardiovascular Center

🇺🇸

Jacksonville, Florida, United States

Kidney & HTN Specialists of Miami

🇺🇸

Miami, Florida, United States

Naples Community Hospital

🇺🇸

Naples, Florida, United States

Scroll for more (69 remaining)
North America Research Institute
🇺🇸Azusa, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.